# US 2015/0031667 A1 · Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031667 A1
- Document ID: US20150031667A1
- Status: Published application
- Kind: A1
- Application number: 14/321,246
- Filed: 2014-07-01
- Published: 2015-01-29
- Earliest claimed: 2009-07-09
- Assignees: Array BioPharma Inc.
- Applicants: Array BioPharma Inc.
- Inventors: Shelley Allen; Steven Wade Andrews; Kevin Ronald Condroski; Julia Haas; Lily Huang; Yutong Jiang; Timothy Krecher; Jeongbeob Seo
- Web page: https://patentgrep.com/patent/US20150031667A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 35/00: Antineoplastic agents
- C07D 453/02: containing not further condensed quinuclidine ring systems
- C07D 471/22: in which the condensed systems contains four or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D 498/22: in which the condensed system contains four or more hetero rings
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compounds of Formula I: and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

## Claims

### Claim 1

A method for treating a disease, condition or disorder mediated by Trk receptor activity in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of formula I
or a pharmaceutically acceptable salt thereof, wherein:
R1 is H or (1-6C alkyl);
R2 is H, (1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)difluoroalkyl, -(1-6C)trifluoroalkyl, -(1-6C)chloroalkyl, -(2-6C)chlorofluoroalkyl, -(2-6C)difluorochloroalkyl, -(2-6C)chlorohydroxyalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, -(1-6C alkyl)NHSO2(1-3C alkyl), -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)2, -(1-6C alkyl)NHC(═O)O(1-4C alkyl), -(1-6C alkyl)hetCyc1, -(1-6C alkyl)hetAr1, hetAr2, hetCyc2, —O (1-6C alkyl) which is optionally substituted with halogen, OH or (1-4C)alkoxy, —O(3-6C cycloalkyl), Cyc1, -(1-6C alkyl)(3-6C cycloalkyl), -(1-6Calkyl)(1-4C alkoxy), -(1-6C hydroxyalkyl)(1-4C alkoxy), a bridged 7-membered cycloalkyl ring optionally substituted with (1-6C)hydroxyalkyl, or a bridged 7-8 membered heterocyclic ring having 1-2 ring nitrogen atoms;
or NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from (1-6C)alkyl, OH, CO2H, (1-3C alkyl)CO2H, —O (1-6C alkyl) and (1-6C)hydroxyalkyl;
hetCyc1 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc1 is optionally substituted with oxo, OH, halogen or (1-6C)alkyl;
hetCyc2 is a 6 membered carbon-linked heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc2 is optionally substituted with F, SO2NH2, SO2(1-3C alkyl) or halogen;
hetAr1 is a 5-membered heteroaryl ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with (1-4C)alkyl;
hetAr2 is a 5-6 membered heteroaryl ring having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-4C)alkyl, (3-6C)cycloalkyl, halogen and OH;
Cyc1 is a 3-6 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H, -(1-4C alkyl)OH, halogen and CF3;
Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3, -(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl), or (ii) a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl), (1-4C)alkyl and NH2, or (iii) a pyrid-2-on-3-yl ring optionally substituted with one or more substituents independently selected from halogen and (1-4C)alkyl;
hetCyc3 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with (1-6C)alkyl;
X is —CH2—, —CH2CH2—, —CH2O— or —CH2NRd—;
Rd is H or -(1-4C alkyl);
R3 is H or -(1-4C alkyl);
each R4 is independently selected from halogen, -(1-4C)alkyl, —OH, -(1-4C)alkoxy, —NH2, —NH(1-4C alkyl) and —CH2OH; and
n is 0, 1, 2, 3, 4, 5 or 6.

### Claim 2 (depends on 1)

The method of claim 1, wherein:
R1 is H or -(1-6C alkyl);
R2 is H, -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, -(1-6C alkyl)NHSO2(1-3C alkyl), -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)2, -(1-6C alkyl)hetCyc1, -(1-6C alkyl)hetAr1, hetAr2, hetCyc2, —O(1-6C alkyl), —O(3-6C cycloalkyl), Cyc1, or a bridged 7-membered cycloalkyl ring,
or NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, —OH, —CO2H and -(1-3C alkyl)CO2H;
hetCyc1 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc1 is optionally substituted with oxo;
hetCyc2 is a 6 membered carbon-linked heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc2 is optionally substituted with F, SO2NH2, or SO2(1-3C alkyl);
hetAr1 is a 5-membered heteroaryl ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with -(1-4C)alkyl;
hetAr2 is a 5-6 membered heteroaryl ring having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from -(1-4C)alkyl;
Cyc1 is 3-6 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H and -(1-4C alkyl)OH;
Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, -(1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3 and —O(1-4C alkyl)O(1-3C alkyl), or (ii) a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl) and (1-4C)alkyl;
hetCyc3 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;
X is —CH2—, —CH2CH2—, —CH2O— or —CH2NRd—;
Rd is H or -(1-4C alkyl);
R3 is H or -(1-4C alkyl);
each R4 is independently selected from halogen, -(1-4C)alkyl, —OH, -(1-4C)alkoxy, NH2, NH(1-4C alkyl) and CH2OH; and
n is 0, 1, 2, 3, 4, 5 or 6.

### Claim 3 (depends on 1)

The method of claim 1, wherein:
R1 is H or -(1-6C alkyl); and
R2 is H, -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, -(1-6C alkyl)NHSO2(1-3C alkyl), -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)2, -(1-6C alkyl)hetCyc1, -(1-6C alkyl)hetAr1, hetAr2, —O(1-6C alkyl), —O(3-6C cycloalkyl), or a 3, 4 or 5 membered cycloalkyl ring optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H and -(1-4C alkyl)OH,
or NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, —OH, —CO2H and -(1-3C alkyl)CO2H.

### Claim 4 (depends on 1)

The method of claim 1, wherein:
R1 is H or -(1-6C alkyl);
R2 is H, -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, -(1-6C alkyl)NHSO2(1-3C alkyl), -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)2, -(1-6C alkyl)hetCyc1, -(1-6C alkyl)hetAr1, hetAr2, hetCyc2, —O(1-6C alkyl), —O(3-6C cycloalkyl), or a bridged 7-membered cycloalkyl ring,
or NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, —OH, —CO2H and -(1-3C alkyl)CO2H.

### Claim 5 (depends on 1)

The method of claim 1, wherein R2 is H or -(1-6C)alkyl.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The method of claim 5, wherein R2 is methyl, ethyl, isopropyl or tert-butyl.

### Claim 8 (depends on 5)

The method of claim 5, wherein R2 is H.

### Claim 9 (depends on 1)

The method of claim 1, wherein R2 is -(1-6C)hydroxyalkyl or -(2-6C)dihydroxyalkyl.

### Claim 10 (depends on 9)

The method of claim 9, wherein R2 is CH2CH2OH, CH2CH(OH)CH2OH or C(CH3)(CH2OH)2.

### Claim 11 (depends on 1)

The method of claim 1, wherein R2 is Cyc1 or a bridged 7-membered cycloalkyl ring.

### Claim 12 (depends on 11)

The method of claim 11, wherein R2 is Cyc1 optionally substituted with optionally substituted with one or two substituents independently selected from methyl, —OH, —CH2OH and —CO2H.

### Claim 13 (depends on 12)

The method of claim 12, wherein R2 is cyclopropyl.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein Cyc1 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H, -(1-4C alkyl)OH, halogen and CF3.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein R2 is cyclopropyl optionally substituted with one or more substituents independently selected from methyl, —CO2H, or —CH2OH.

### Claim 18 (depends on 1)

The method of claim 1, wherein R2 is —O(1-6C alkyl) or —O(3-6C cycloalkyl).

### Claim 19 (depends on 18)

The method of claim 18, wherein R2 is selected from —OMe, —OEt and cyclopropoxy.

### Claim 20 (depends on 1)

The method of claim 1, wherein R2 is selected from -(1-6C)fluoroalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, and -(1-6C alkyl)NHSO2(1-3C alkyl).

### Claim 21 (depends on 20)

The method of claim 20, wherein R2 is selected from —C(CH3)2CH2F, —C(CH3)2CH2OH, CH2C(CH3)2OH, —CH2CN, —C(CH3)2CN, —CH2CH2SO2NH2, —CH2CH2NHSO2CH3 and —C(CH3)2CH2NHSO2CH3.

### Claim 22 (depends on 1)

The method of claim 1, wherein R2 is selected from -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl) and -(1-6C alkyl)N(1-4C alkyl)2.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The method of claim 1, wherein R2 is selected from -(1-6C alkyl)hetCyc1 and -(1-6C alkyl)hetAr1.

### Claim 25 (depends on 1)

The method of claim 1, wherein R2 is selected from -(1-6C alkyl)hetAr1 and hetAr2.

### Claim 26 (depends on 1)

The method of claim 1, wherein R1 is H.

### Claim 27 (depends on 1)

The method of claim 1, wherein NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, —OH, —CO2H and -(1-3C alkyl)CO2H.

### Claim 28 (depends on 1)

The method of claim 1, wherein X is —CH2— or —CH2CH2—.

### Claim 29

(canceled)

### Claim 30 (depends on 1)

The method of claim 1, wherein X is —CH2O— or —CH2NRd—.

### Claim 31

(canceled)

### Claim 32 (depends on 1)

The method of claim 1, wherein Y is phenyl optionally substituted with one or more substituents independently selected from halogen, -(1-4C)alkoxy, CF3, CHF2, —O(1-4C alkyl)hetCyc3, -(1-4C alkyl)hetCyc3 and —O(1-4C alkyl)O(1-3C alkyl).

### Claim 33 (depends on 32)

The method of claim 32, wherein Y is phenyl optionally substituted with one or more substituents independently selected from —F, —Cl, —OMe, —CF3, —CHF2, morpholinylethoxy, morpholinylethyl and —OCH2CH2OMe.

### Claim 34 (depends on 33)

The method of claim 33, wherein Y is phenyl, 3-fluorophenyl, 2,5-difluorophenyl, 2-chloro-5-fluorophenyl, 2-methoxyphenyl, 2-methoxy-5-fluorophenyl, 2-trifluoromethyl-5-fluorophenyl, 2-difluoromethyl-5-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-(2-morpholinylethoxyl)phenyl, 3-fluoro-5-(2-morpholinylethyl)phenyl, 5-fluoro-2-(2-morpholinylethyl)phenyl, 3-fluoro-5-methoxyethoxyphenyl or 5-fluoro-2-methoxyethoxyphenyl.

### Claim 35 (depends on 1)

The method of claim 1, wherein Y is fluorophenyl optionally substituted with a substituent selected from —O(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl).

### Claim 36 (depends on 35)

The method of claim 35, wherein Y is fluorophenyl substituted with a substituent selected from morpholinylethoxy, —OCH2CH2OMe, 2,3-dihydroxypropoxy and 2,2-dimethyl-1,3-dioxolanyl.

### Claim 37 (depends on 34)

The method of claim 34, wherein Y is 2,5-difluorophenyl.

### Claim 38 (depends on 1)

The method of claim 1, wherein Y is a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl) and (1-4C)alkyl.

### Claim 39 (depends on 38)

The method of claim 38, wherein Y is pyridyl optionally substituted with one or more substituents independently selected from F, —OMe, ethyl and Me.

### Claim 40 (depends on 39)

The method of claim 39, wherein Y is pyrid-2-yl, pyrid-3-yl, 5-fluoropyrid-3-yl, 2-methoxy-5-fluoropyridy-3-yl, 2-ethyl-5-fluoropyrid-3-yl or 2-methyl-5-fluoropyridy-3-yl.

### Claim at position 41

41-44. (canceled)

### Claim 45 (depends on 1)

The method of claim 1, wherein Y is a pyrid-2-on-3-yl ring optionally substituted with one or more substituents independently selected form halogen and (1-4C)alkyl.

### Claim 46 (depends on 45)

The method of claim 45, wherein Y is 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl.

### Claim 47 (depends on 1)

The method of claim 1, wherein:
R1 is H or -(1-6C alkyl);
R2 is H, -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, -(1-6C alkyl)NHSO2(1-3C alkyl), -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)2, -(1-6C alkyl)hetCyc1, -(1-6C alkyl)hetAr1, hetAr2, hetCyc2, —O(1-6C alkyl), —O(3-6C cycloalkyl), or Cyc1;
or NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, —OH, —CO2H and -(1-3C alkyl)CO2H;
Cyc1 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H and -(1-4C alkyl)OH.
X is CH2; and
Y is (i) fluorophenyl optionally substituted with a substituent selected from —O (1-4C alkyl)hetCyc3, -(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl), (ii) pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl, or (iii) 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl.

### Claim at position 45

48-51. (canceled)

### Claim 52 (depends on 1)

The method of claim 1, wherein R4 is OH, F, methyl, or CH2OH.

### Claim 53 (depends on 52)

The method of claim 52, wherein n is 0, 1 or 2.

### Claim 54

(canceled)

### Claim 55 (depends on 1)

The method of claim 1, wherein Y has the absolute configuration of Figure Ia:

### Claim 56 (depends on 1)

The method of claim 1, wherein R3 is H.

### Claim 57 (depends on 1)

The method of claim 1, wherein n is 0-2 and R4 is F or Me.

### Claim 58 (depends on 57)

The method of claim 57, wherein n is 0.

### Claim 59

(canceled)

### Claim 60 (depends on 1)

The method for of claim 1, wherein said disease, condition or disorder is selected from the group consisting of pain, cancer, inflammation, neurodegenerative disease and Trypanosoma cruzi infection.

### Claim at position 55

61-63. (canceled)
